Navigating The Regulatory Landscape Of mRNA-Based Therapeutics

In recent years, RNA-based therapeutics—particularly small interfering RNA (siRNA) and messenger RNA (mRNA) drugs—have significantly transformed the landscape of modern medicine. These innovative therapies have opened new avenues for treating a wide range of diseases, from genetic disorders to infectious diseases and cancer. As the field continues to evolve, understanding the regulatory frameworks that govern these therapies is crucial for successful development and commercialization. This webinar will provide an in-depth exploration of how mRNA-based therapeutics are categorized and regulated in both the European Union and the United States.

Stay informed on the latest regulatory developments affecting mRNA therapeutics—from drug substance production to final LNP formulation—and discover strategic opportunities to optimize your mRNA drug development pipelines in an increasingly complex global regulatory environment.